ZIVO Bioscience Crecimiento futuro

Future controles de criterios 2/6

Se prevé que los beneficios de ZIVO Bioscience disminuyan a un ritmo anual de 3.7%, mientras que sus ingresos anuales crecerán a un ritmo de 106.6% por año. Se espera que el BPA crezca en un 37.7% al año.

Información clave

-8.7%

Tasa de crecimiento de los beneficios

27.1%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Personal Products	23.8%
Tasa de crecimiento de los ingresos	117.9%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	11 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

ZIVO Bioscience: Building An IP Portfolio For Algal Biomass Derived Ingredients

Nov 25

Previsiones de crecimiento de beneficios e ingresos

OTCPK:ZIVO - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	2	-8	N/A	N/A	1
12/31/2024	1	-8	N/A	N/A	1
3/31/2024	0	-7	-5	-5	N/A
12/31/2023	0	-8	-6	-6	N/A
9/30/2023	0	-9	-7	-7	N/A
6/30/2023	0	-9	-6	-6	N/A
3/31/2023	N/A	-9	-6	-6	N/A
12/31/2022	N/A	-9	-7	-7	N/A
9/30/2022	N/A	-9	-8	-8	N/A
6/30/2022	N/A	-9	-8	-8	N/A
3/31/2022	N/A	-9	-9	-9	N/A
12/31/2021	N/A	-9	-7	-7	N/A
9/30/2021	N/A	-7	-6	-6	N/A
6/30/2021	N/A	-9	-5	-5	N/A
3/31/2021	N/A	-9	-3	-3	N/A
12/31/2020	0	-9	-3	-3	N/A
9/30/2020	0	-11	-2	-2	N/A
6/30/2020	0	-10	-3	-3	N/A
3/31/2020	0	-11	-4	-4	N/A
12/31/2019	N/A	-12	-4	-4	N/A
9/30/2019	N/A	-10	-4	-4	N/A
6/30/2019	N/A	-13	-4	-4	N/A
3/31/2019	N/A	-14	-5	-5	N/A
12/31/2018	N/A	-15	-5	-5	N/A
9/30/2018	N/A	-15	-5	-5	N/A
6/30/2018	N/A	-14	-5	-5	N/A
3/31/2018	N/A	-12	-5	-5	N/A
12/31/2017	N/A	-10	N/A	-4	N/A
9/30/2017	N/A	-7	N/A	-4	N/A
6/30/2017	N/A	-6	N/A	-3	N/A
3/31/2017	N/A	-7	N/A	-2	N/A
12/31/2016	N/A	-6	N/A	-3	N/A
9/30/2016	N/A	-6	N/A	-2	N/A
6/30/2016	N/A	-6	N/A	-2	N/A
3/31/2016	N/A	-6	N/A	-3	N/A
12/31/2015	N/A	-6	N/A	-2	N/A
9/30/2015	N/A	-4	N/A	-2	N/A
6/30/2015	N/A	-6	N/A	-3	N/A
3/31/2015	N/A	-5	N/A	-2	N/A
12/31/2014	N/A	1	N/A	-3	N/A
9/30/2014	N/A	0	N/A	-3	N/A
6/30/2014	N/A	-1	N/A	-3	N/A
3/31/2014	N/A	-5	N/A	-3	N/A
12/31/2013	N/A	-10	N/A	-3	N/A
9/30/2013	N/A	-11	N/A	-3	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que ZIVO siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que ZIVO siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que ZIVO siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (106.6% al año) de ZIVO crezcan más rápidamente que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (106.6% al año) de ZIVO crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de ZIVO se prevé que sea elevada dentro de 3 años.

ZIVO Bioscience Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

ZIVO Bioscience, Inc., Annual General Meeting, Jun 11, 2024

The Nasdaq Stock Market to Delist the Common Stock of ZIVO Bioscience

ZIVO Bioscience, Inc. Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study

Zivo Bioscience Reports Positive Efficacy Results from 42-Day Validation Study with Non-Antibiotic Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens

ZIVO Bioscience, Inc. announced that it has received $0.531142 million in funding

Nasdaq Determines to Delist the ZIVO Bioscience's Common Stock from the Nasdaq Capital Market

Nasdaq Determines to Delist the ZIVO Bioscience's Common Stock from the Nasdaq Capital Market

New major risk - Share price stability

ZIVO Bioscience Announces Reverse Stock Split to Regain Compliance with the Nasdaq Stock Market’s Continued Listing Requirements

New major risk - Market cap size

Trial Results Confirm Efficacy of ZIVO Bioscience’s Non-Antibiotic Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens

Nasdaq Hearings Panel Grants Zivo Biosciences's Request to Provide an Extension Until November 20, 2023 to Regain Compliance with the Stockholders’ Equity Rule for Continued Listing on Nasdaq

New minor risk - Shareholder dilution

Zivo Bioscience, Inc. Announces its GRAS Designation Reaffirmed for Proprietary Algal Biomass Product as Human Food Ingredient

Nasdaq Notifies Zivo Biosciences Regarding its Common Stock Delisting from Nasdaq Due to Non-Compliance with the Stockholders’ Equity Requirement

ZIVO Bioscience, Inc. Announces Results of Study with Its Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens

Independent Director recently bought US$72k worth of stock

Zivo Bioscience Receives Written Notice from the Nasdaq Stock Market

ZIVO Bioscience, Inc. Reports USDA Claims Regulatory Jurisdiction for New Coccidiosis Treatment

ZIVO Bioscience, Inc., Annual General Meeting, Jul 28, 2022

ZIVO Bioscience Regains Compliance Following Receipt of Non-Compliance Notice from Nasdaq

ZIVO Bioscience, Inc. announced delayed annual 10-K filing

Independent Director recently bought US$340k worth of stock

ZIVO Bioscience: Building An IP Portfolio For Algal Biomass Derived Ingredients

Independent Director Robert Rondeau has left the company

ZIVO Bioscience, Inc. has completed a Composite Units Offering in the amount of $13.8 million.

ZIVO Bioscience, Inc. Announces Us Patent Office Notice of Allowance for Administration of Proprietary Algal Biomass to Support Immune Health

ZIVO Bioscience, Inc. Appoints Alison A. Cornell as Member of the Board

ZIVO Bioscience, Inc. Announces Executive Changes

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento